Usmarapride
SUVN-D4010 · SUVN-D-4010
Last updated
At a glance
Overview
Why Usmarapride#
Usmarapride (SUVN-D4010) is a selective 5-HT4 receptor partial agonist out of Suven Life Sciences that has earned its place in serious nootropic stacks for two reasons: it drives cortical acetylcholine release upstream of where donepezil acts, and it elevates sAPPα — the neurotrophic, non-amyloidogenic fragment of APP. The community running it isn't chasing an acute stimulant feel; it's chasing the cumulative shift in verbal recall, learning rate, and memory consolidation that the preclinical and Phase 1 data point toward.
It cleared a clean Phase 1 program — single doses to 45 mg, 14-day multiple doses to 40 mg QD — without ECG, hepatic, or CNS safety signals, which is unusually solid for a research-tier nootropic. Once-daily oral dosing, steady state by day 2, food-independent AUC, and no HPTA or endocrine activity make it operationally simple to slot into a longevity, looksmaxxing, or on-cycle cognitive-maintenance protocol.
"Usmarapride demonstrated high in vitro potency and selectivity as a 5-HT4 partial agonist, produced robust cortical acetylcholine release, and elevated sAPPα in vivo, reflecting a mechanism that supports memory and neuroprotection." — Nirogi et al., J Med Chem (2021)
The sections below cover documented usmarapride dosage ranges, the ACD856 / choline / donepezil stacking logic, Phase 1 pharmacokinetics and sex/age exposure differences, the side-effect profile, and the community-practice pitfalls (skipping choline, quitting at day 3, chasing dose past 40 mg) that flatten results.
How Usmarapride works
5-HT4 Receptor Partial Agonism#
Usmarapride is a high-affinity, highly selective partial agonist at the 5-HT4 serotonin receptor — a Gs-coupled GPCR densely expressed in the hippocampus, prefrontal cortex, amygdala, and striatum. These are exactly the regions where 5-HT4R density falls in age- and Alzheimer's-related cognitive decline, which is the structural rationale for targeting this receptor for memory and learning.
Partial agonism matters here. A full agonist at 5-HT4R would drive the receptor system into desensitization and tolerance — the same problem that limits many monoaminergic drugs. A partial agonist sets a ceiling on receptor activation, which is why the Phase 1 program was able to dose up to 40 mg QD for 14 days without dose-limiting toxicity and why the compound is suited to chronic, daily protocols rather than pulsed administration.
"Usmarapride demonstrated high in vitro potency and selectivity as a 5-HT4 partial agonist, produced robust cortical acetylcholine release, and elevated sAPPα in vivo, reflecting a mechanism that supports memory and neuroprotection." — Nirogi R, Mohammed AR, Shinde AK, et al. Journal of Medicinal Chemistry, 2021
Selectivity versus 5-HT3 (the receptor responsible for the nausea seen with older, non-selective benzamide 5-HT4 ligands like cisapride and mosapride) is the other reason the clinical AE profile is mild. Despite the "-pride" stem, the scaffold is an indazole-oxadiazole-piperidine — structurally unrelated to the benzamide prokinetics.
Cortical Acetylcholine Release#
The downstream consequence of 5-HT4R activation in cortex is cholinergic facilitation. 5-HT4R signalling raises intracellular cAMP through PKA, which increases acetylcholine (ACh) release from cholinergic terminals projecting into the cortex and hippocampus. Usmarapride reproduces this effect dose-dependently in rats.
"Cognitive enhancement was observed in multiple preclinical models, including novel object recognition and Morris water maze, and usmarapride produced additive pro-cognitive effects when combined with sub-threshold donepezil." — Nirogi R, Grandhi VR, Medapati R, et al. European Journal of Pharmacology, 2023
This is the same neurotransmitter system targeted by donepezil, rivastigmine, and the choline donors (alpha-GPC, CDP-choline) the nootropic community already runs — but usmarapride acts upstream, driving release rather than substrate availability or breakdown. That's the mechanistic basis for the three-lever cholinergic stack documented in community protocols:
| Lever | Compound | Mechanism |
|---|---|---|
| Substrate | alpha-GPC / CDP-choline | Supplies choline for ACh synthesis |
| Release | Usmarapride | 5-HT4R-driven cortical ACh release |
| Breakdown | Donepezil (optional) | Acetylcholinesterase inhibition |
The practical endpoint is verbal recall, learning rate, and working-memory throughput — the same cognitive axes that dull on long AAS blocks, in sleep-compressed schedules, and with age.
Non-Amyloidogenic APP Processing and sAPPα Elevation#
5-HT4R activation shifts amyloid precursor protein (APP) processing toward the α-secretase pathway, releasing the neurotrophic, neuroprotective fragment sAPPα while reducing flux through the β-secretase pathway that generates Aβ. Usmarapride elevated sAPPα dose-dependently in preclinical models.
This is the disease-modifying arm of the mechanism, distinct from the acute cholinergic-cognitive arm. sAPPα promotes neurite outgrowth, synaptic plasticity, and neuronal survival. For physique- and longevity-focused users running 12+ week blocks, this is the mechanism that justifies chronic low-dose administration rather than pulsed use — the sAPPα effect is cumulative and builds with steady-state exposure, which is reached by day 2 of once-daily dosing.
Pro-Cognitive Efficacy Across Memory Domains#
Translation of receptor pharmacology into behavioural endpoints is where 5-HT4 agonists earn their reputation. Usmarapride produced cognitive enhancement in rodents across episodic, working, social, and emotional memory paradigms — novel object recognition, social recognition, Morris water maze, and fear conditioning — at oral exposures matched to the clinical Phase 1 PK.
The donepezil-potentiation finding is mechanistically important: at sub-threshold doses of donepezil that produced no effect on their own, addition of usmarapride produced an additive cognitive signal. Two upstream/downstream levers on the same neurotransmitter system stack rather than redundantly compete, which is the same logic that justifies pairing usmarapride with TrkB-PAMs like ACD856 in the Everychem-style neurotrophic stack — different receptor, convergent endpoint.
Clinical Safety Anchor#
The mechanism is well-behaved in humans at the dose range community protocols draw from.
"Usmarapride was well tolerated at single doses up to 45 mg and multiple doses up to 40 mg QD for 14 days. No significant ECG, hepatic, or central nervous system safety findings emerged in healthy subjects." — Nirogi R, Bhyrapuneni G, Muddana NR, et al. Clinical Drug Investigation, 2021
The absence of an ECG signal is the headline finding. The older non-selective 5-HT4 agonists (cisapride) were withdrawn for hERG-mediated QT prolongation; usmarapride's selectivity profile and the clinical ECG data argue that this class-level concern does not extend to this molecule at the doses used. The cognitive payload — cortical ACh release, sAPPα elevation, partial-agonist-driven plasticity — therefore lands without the cardiac liability that sank the first generation of this class.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 5–10 mg | Once daily | Documented entry-level range |
| Mid | 15–25 mg | Once daily | Most commonly studied range |
| High | 30–40 mg | Once daily | Administered once daily in the morning. Food does not affect total exposure (AUC) but delays Tmax by ~1.5h. Steady state is reached by day 2; cognitive endpoints build over the first 1–4 weeks rather than appearing acutely. |
Cycle length & outcomes
Documented cycle
4–12 weeks
Plateau after
12 wks
Cycle Notes#
Usmarapride is a chronic-administration nootropic, not a pulsed cycle compound. The mechanism — upstream cholinergic facilitation, sAPPα elevation, and 5-HT4-driven shifts in APP processing — is cumulative. Steady state is reached by day 2 of once-daily dosing (accumulation ratio 1.3–1.4×), but the cognitive endpoints that matter (verbal recall, learning rate, working memory, low-grade mood lift) build over 1–4 weeks as the downstream neurochemistry shifts.
This is the opposite of a stimulant. Subjects expecting an acute "feel" on day one consistently quit too early. The Phase 1 PK and the preclinical timeline both point to a slow-burn molecule.
Cycle Length by Goal#
| Goal | Cycle Length | Daily Dose |
|---|---|---|
| Exploratory / titration | 2–4 weeks | 5–10 mg |
| Standard cognition / memory | 6–8 weeks | 15–25 mg |
| Cholinergic stack (with alpha-GPC ± donepezil) | 8–12 weeks | 15–20 mg |
| Neuroprotective / longevity block | 12+ weeks | 10–20 mg |
| Upper-bound exploratory | 4–8 weeks | 30–40 mg |
| On-cycle cognitive maintenance (AAS adjunct) | matches AAS block | 10–20 mg |
The 40 mg ceiling is anchored to the multiple-ascending-dose study, where 40 mg QD for 14 days was tolerated without dose-limiting toxicity. Single doses to 45 mg were also cleared. No published data supports going higher, and partial agonists tend to plateau rather than reward escalation.
"Usmarapride was well tolerated at single doses up to 45 mg and multiple doses up to 40 mg QD for 14 days. No significant ECG, hepatic, or central nervous system safety findings emerged in healthy subjects." — Nirogi et al., Clin Drug Investig (2021)
Loading, Tapering, Timing#
- No loading dose. Steady state lands by day 2 on a flat QD schedule — front-loading offers nothing and only raises the AE ceiling (headache, mild nausea, GI acceleration).
- No taper required. Usmarapride is non-hormonal, non-suppressive, and does not produce tolerance or withdrawal in the Phase 1 record. Discontinuation is abrupt without consequence.
- Morning administration, once daily. Fed or fasted is operationally equivalent — food delays Tmax by ~1.5 h but does not change AUC.
- Onset: subtle shifts within 3–5 days as steady state is reached; meaningful endpoints (verbal fluency, recall, learning rate) shift over weeks, mirroring the rodent timeline.
"Cognitive enhancement was observed in multiple preclinical models, including novel object recognition and Morris water maze, and usmarapride produced additive pro-cognitive effects when combined with sub-threshold donepezil." — Nirogi et al., Eur J Pharmacol (2023)
Dose Calibration by Subject#
Phase 1 PK showed female and elderly (≥65) subjects reach ~60–65% of young-adult-male exposure at matched mg doses. The practical read:
| Subject | Calibration |
|---|---|
| Young adult male, ≤90 kg | Standard band (15–25 mg) |
| Young adult male, >100 kg | Upper end of standard band (20–25 mg) |
| Female users | Upper end of standard band (20–25 mg) |
| Users ≥65 | Upper end of standard band (20–25 mg) |
| Stacking with a TrkB-PAM (ACD856) or M1-PAM (AF710B) | Mid-band (15–20 mg) — additive mechanisms, no need to push |
Bloodwork & Monitoring Cadence#
The Phase 1 record is unusually clean for a CNS molecule — no flagged hepatic, hematologic, lipid, glucose, or vital-sign signals through 14 days at the top dose. Routine on-cycle labs are not mechanism-driven here.
What is worth tracking:
- Baseline ECG for users with personal or family cardiac history. The class-level QT concern (cisapride, the older non-selective 5-HT4 agonists) did not reproduce in usmarapride Phase 1, but a baseline + 8-week ECG is cheap due diligence. Hard contraindication remains for long-QT syndrome and concurrent QT-prolonging polypharmacy.
- Subjective cognitive testing at baseline and 4-week intervals — Cambridge Brain Sciences battery, dual-n-back, or a paper RAVLT-style word-list test. This is the most useful endpoint, since the effect size is real but not dramatic and is easy to gaslight oneself about.
- GI transit — 5-HT4R is densely expressed in gut smooth muscle (prucalopride uses the same target for chronic constipation). Loose stools or accelerated transit at the 30–40 mg end is mild and self-resolving but worth noting.
Stacking the Cycle#
The dominant community pairing is usmarapride + a choline donor, on the logic that the molecule upstream-drives ACh release and benefits from guaranteed substrate:
- Alpha-GPC 300–600 mg QD, or
- CDP-choline 250–500 mg QD
The expanded Everychem-style stack adds ACD856 (TrkB/BDNF positive allosteric modulator) for a "cognition + neurotrophic" pairing, and optionally AF710B (M1 PAM) for users targeting cholinergic tone from multiple angles. Low-dose donepezil (2.5–5 mg every other day) is the third lever for users already comfortable with AChEIs — preclinical work showed additive cognitive effects with sub-threshold donepezil.
No PK interactions are known with AAS, AIs, PDE5 inhibitors, finasteride/dutasteride, or standard on-cycle ancillaries. Usmarapride slots into a blast/cruise or hair stack without rearranging anything.
When to Stop#
- Headache or nausea that doesn't resolve within the first 7–10 days — reduce dose by half or discontinue
- No subjective or objective change at 8 weeks on a 20–25 mg protocol with adequate choline — the molecule is unlikely to be the right tool for that user
- Any new QT-prolonging medication added to the regimen
Otherwise, this is a compound the community runs as an open-ended chronic block, reassessed every 8–12 weeks against objective testing. The mechanism is designed for chronic use, the Phase 1 safety record supports it, and the disease-modifying endpoint (sAPPα elevation, non-amyloidogenic APP processing) is mechanistically chronic.
Risks & mistakes
Common (most users)#
- Headache — the most frequently reported AE in the Phase 1 program, typically mild and transient. Adequate hydration and dosing alongside breakfast generally resolves it; if it persists past the first week, dropping back one dose tier is the simplest fix.
- Mild nausea — uncommon at the lower end of the band but more visible as doses climb into the 25–40mg range. Administration with food blunts it without sacrificing AUC, since food only delays Tmax by ~1.5h and does not change total exposure.
- Loose stools / accelerated GI transit — a class effect. 5-HT4 receptors are densely expressed in gut smooth muscle (the same biology prucalopride exploits clinically for constipation). Usually settles within a few days as steady state stabilises; if not, the protocol calls for a one-step dose reduction.
- Subtle stim-like alerting in the first few hours post-dose — most users find this neutral or pleasant. Morning administration keeps any residual signal away from sleep onset.
"Usmarapride was well tolerated at single doses up to 45 mg and multiple doses up to 40 mg QD for 14 days. No significant ECG, hepatic, or central nervous system safety findings emerged in healthy subjects." — Nirogi R, Bhyrapuneni G, Muddana NR, et al., Clinical Drug Investigation (2021)
Uncommon (dose-dependent or individual)#
- Persistent GI looseness at 30–40mg — the upper end of the documented MAD range. If stools remain loose past the first week at this dose, stepping down to 20–25mg generally restores normal transit while preserving the cognitive endpoint.
- Sleep-onset disturbance with late-day dosing — the cholinergic facilitation that drives the cognitive endpoint can fragment sleep if dosing drifts into the afternoon. Strict AM administration resolves it.
- Flat / blunted response in users without choline support — not a side effect strictly, but the most common reason logs underwhelm. Substrate-limited cholinergic systems can't capitalise on increased release; pairing with alpha-GPC 300–600mg or CDP-choline 250–500mg corrects this.
- Heightened serotonergic load in users already on SSRIs/SNRIs — no clinical signal in Phase 1, but 5-HT4 partial agonism layers on top of existing serotonergic tone. Bloodwork is not informative here; symptomatic monitoring (jaw clenching, agitation, GI) is the sensible approach, and conservative dose laddering from 5mg upward is rational for stacked users.
Rare but serious#
- QT prolongation — the older, non-selective 5-HT4 agonists (cisapride was withdrawn for this) produced QT effects via hERG channel block. Usmarapride is selective and Phase 1 ECG monitoring did not flag QTc changes at single doses to 45mg or 14-day dosing to 40mg QD. Still, the class-level concern carries a baseline-ECG-then-recheck habit for users with cardiac history. Warning signs: palpitations, syncope, presyncope — discontinue and seek evaluation.
- Serotonin syndrome (theoretical) — no clinical signal, but mechanistically plausible if combined with MAOIs, linezolid, or high-dose serotonergic polypharmacy. Hyperthermia, clonus, agitation, autonomic instability — discontinue immediately.
- Marked GI cramping or bleeding — not reported in the Phase 1 cohort, but any high-affinity GI prokinetic action warrants discontinuation if frank cramping or bleeding emerges.
"Cognitive enhancement was observed in multiple preclinical models, including novel object recognition and Morris water maze, and usmarapride produced additive pro-cognitive effects when combined with sub-threshold donepezil." — Nirogi R, Grandhi VR, Medapati R, et al., European Journal of Pharmacology (2023)
Hard contraindications#
- Long-QT syndrome (personal or family history) — class-level caution; the line does not get crossed.
- Concurrent QT-prolonging polypharmacy — macrolide antibiotics, fluoroquinolones, ondansetron at high dose, certain antipsychotics, methadone, class III antiarrhythmics. Do not stack.
- MAOI co-administration — including selegiline, phenelzine, tranylcypromine, and the dietary-relevant linezolid. The serotonergic interaction risk is not worth the speculative upside.
- Pregnancy and lactation — zero reproductive toxicology data in the public literature. Avoid.
Gender, age, and PCT considerations#
Female subjects and elderly (≥65) subjects reach roughly 60–65% of young-adult-male exposure at matched mg doses in the Phase 1 PK work — meaning calibration toward the upper end of the standard band is rational for these groups rather than the lower end. This is a PK adjustment, not a safety contraindication.
Usmarapride is non-hormonal, non-steroidal, and non-suppressive. It does not bind androgen, estrogen, or progesterone receptors; it does not affect the HPTA; it does not alter LH, FSH, testosterone, prolactin, or any reproductive endocrine axis. No PCT is required, no ancillary AI/SERM is required, and the compound stacks cleanly alongside AAS cycles, hair stacks, and PDE5 protocols without endocrine cross-talk. It is also safe in physique-focused female users — the only adjustment is the modestly lower exposure at a given mg dose.
FAQ — Usmarapride
Research & citations
5 studies cited on this page.
Conclusion
Usmarapride stands out in the nootropic space as a highly selective 5-HT4 partial agonist with robust evidence for cognitive enhancement and neuroprotection. The documented protocols are straightforward, with wide tolerability and an unusually clean safety profile for a research-phase compound.
Key takeaways:
- Typical daily dose: 15–25 mg PO once daily; dosing can range from 5–10 mg (exploratory) up to 40 mg (advanced), with no benefit to pushing higher
- Administered orally in the morning; food delays absorption but does not affect total exposure
- Cycle duration: 4–12 weeks, with effects building cumulatively over weeks
- Stacking: best paired with a choline donor (alpha-GPC or CDP-choline); additive effects seen with donepezil and synergy in BDNF-focused stacks (e.g., ACD856)
- Benefits: consistent support for episodic and working memory, learning rate, and subtle mood elevation, with a mechanism linked to increased ACh release and sAPPα neuroprotection
- Side effect profile is mild (headache, nausea); hard contraindications are QT-risk, MAOIs, pregnancy, or lactation
For research models focused on cognitive enhancement, memory consolidation, or neurotrophic support, usmarapride is among the best-characterized 5-HT4 agonists available outside pharma pipelines.